Merck & Co., Inc. is 133.5x more valuable than Enliven Therapeutics, Inc. by market capitalization ($293.16 B vs $2.20 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ELVN | MRK |
|---|---|---|
| Market cap | $2.20 B | $293.16 B |
| US-listed rank | #2035 | #44 |
| Revenue (latest FY) | - | $65.01B |
| Net income (latest FY) | -$103.70M | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 750 | 996 |
Merck & Co., Inc. is 133.5x more valuable than Enliven Therapeutics, Inc. by market capitalization ($293.16 B vs $2.20 B).
Full pages: Enliven Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.